| Filed On | Filing |
|---|---|
| 10 Nov 2026 |
8-K: Results of Operations and Financial Condition
WILMINGTON, Del., November 10, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial ... |
| 20 Oct 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
WILMINGTON, Del., October 20, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial H... |
| 08 Sep 2026 |
8-K: Regulation FD Disclosure
Disclaimer This presentation contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Inhibikase Therapeutics, Inc. (the “Company” or “w... |
| 26 Aug 2026 |
8-K: Changes in Registrant's Certifying Accountant
Inhibikase Therapeutics, Inc. - Changes in Registrant’s Certifying Accountant |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
WILMINGTON, Del., August 11, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hy... |
| 29 Jul 2026 |
8-K: Unregistered Sales of Equity Securities
Inhibikase Therapeutics, Inc. , a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”... |
| 23 Jul 2026 |
8-K: Regulation FD Disclosure
WILMINGTON, Del., July 23, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that the U... |
| 14 Jul 2026 |
8-K: Other Events
WILMINGTON, Del., July 14, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today announced that it ha... |
| 29 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
Inhibikase Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY THAT: |
| 12 May 2026 |
8-K: Results of Operations and Financial Condition
WILMINGTON, Del., May 12, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), today reported financial re... |
| 07 Apr 2026 |
8-K: Regulation FD Disclosure
WILMINGTON, Del., April 7th, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary Arterial Hypertension (“PAH”), announced today that the... |
| 26 Mar 2026 |
8-K: Results of Operations and Financial Condition
WILMINGTON, Del., March 26, 2026 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonar... |
| 19 Dec 2025 |
8-K: Other Events
Securities Registered under Registration Statement on Form S-3 |
| 21 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Other Events
Introductory. Inhibikase Therapeutics, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 46,091,739 shares of its common stoc... |
| 20 Nov 2025 |
8-K: Other Events
Disclaimer This presentation contains information that may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Inhibikase Therapeutics, Inc. (the “Company” or “w... |
| 14 Nov 2025 |
8-K: Results of Operations and Financial Condition
November 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hype... |
| 14 Aug 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
August 14, 2025 — Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypert... |
| 30 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
The 2025 Annual Meeting of Stockholders (the “Annual Meeting”) of Inhibikase Therapeutics, Inc. (the “Company”) was held on June 27, 2025. The following proposals were approved at the Annual Meeting by the votes indicated: |
| 14 May 2025 |
8-K: Results of Operations and Financial Condition
—Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension — |
| 14 Apr 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
This Employment Agreement (“Agreement”) is made between Inhibikase Therapeutics, Inc. (the “Company”), and David McIntyre (the “Executive”) and is effective on the first business day it becomes fully executed (the “Effective Date”). |
Loading...